

EDWIN ZHANG JOINS H.C. WAINWRIGHT AS SENIOR HEALTHCARE ANALYST

NEW YORK, October 22, 2020 – H.C. Wainwright & Co., LLC ("HCW"), a leading investment bank focused on capital markets and equity research in the Life Sciences sector, is pleased to announce that Edwin Zhang has joined the firm as a Managing Director, Equity Research.

Mr. Zhang's research focuses on biotechnology, specifically on companies developing novel drugs in a variety of therapeutic areas. Prior to joining H.C. Wainwright, Mr. Zhang conducted equity research at Stifel and RBC Capital Markets, covering US large and mid-cap biotech companies. Prior to his career in investment banking, Dr. Zhang was a research scientist at New York University Medical Center where his academic research focused on cancer metastasis, developmental disorders and transgenic models. Mr. Zhang's educational background includes a Ph.D. from Texas A&M University and an MBA from NYU Stern School of Business.

"We are excited that Edwin has chosen to become a member of the research team at HCW," commented Mark Viklund, HCW's Chief Executive Officer. "He will be a valued addition to our franchise of 14 senior analysts covering the Life Sciences sector as we continue to expand our breadth of coverage across the market capitalization spectrum."

About H.C. Wainwright & Co.

H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

For more information visit H.C. Wainwright & Co. on the Internet at www.hcwco.com